Advancements in Hormone Receptor-Positive Metastatic Breast Cancer
Virginia Kaklamani, MD, DSc; and Megan Kruse, MD, discuss how advances in hormone receptor-positive metastatic breast cancer treatment, including ESR1 mutation testing and elacestrant therapy, help physicians optimize patient care and improve outcomes through personalized treatment selection.
EP. 2: Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options
May 5th 2025Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.
Watch
EP. 4: EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success
May 8th 2025Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.
Watch
EP. 5: Managing Elacestrant Treatment: From Patient Selection to Supportive Care
May 8th 2025Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.
Watch
